Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 2, 2006, Pages 850-857

  Zhu, Hao Jie ^a   Wang, Jun Sheng ^a   Markowitz, John S ^b   Donovan, Jennifer L ^b   Gibson, Bryan B ^b   Gefroh, Holly A ^b   DeVane, C Lindsay ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CANNABIDIOL; CANNABINOID; CANNABINOL; CANNABIS; DOXORUBICIN; DRONABINOL; FLUORESCENT DYE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; TETRAHYDROCANNABINOLIC ACID; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EFFECT; DRUG PENETRATION; DRUG TRANSPORT; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MICHAELIS MENTEN KINETICS; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BIOLOGICAL TRANSPORT; CANNABINOIDS; CANNABIS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; P-GLYCOPROTEIN; RATS; VERAPAMIL;

EID: 33645841349     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.098541     Document Type: Article

References (40)

1. Abbott NJ, Hughes CC, Revest PA, and Greenwood J (1992) Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 103:23-37.
2. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, and Sikic BI (2001) A phase I trial of doxorubicin, paclitaxel and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res 7:1221-1229.
3. Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B, and Kristensen GB (2001) Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 19:2983-2993.
4. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, and van Tellingen O (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416-4421.
5. Bendayan R, Lee G, and Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
6. Boulton DW, DeVane CL, Liston HL, and Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163-169.
7. Compton WM, Grant BF, Colliver JD, Glantz MD, and Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. J Am Med Assoc 291:2114-2121.
8. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, and Schram K (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40:701-708.
9. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
10. Dey S, Ramachandra M, Pastan I, Gottesman MM, and Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94:10594-10599.
11. Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, Oude Elferink RP, Borst P, and Schinkel AH (1996) Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Investig 97:1211-1218.
12. Fardel O, Morel F, and Guillouzo A (1993) P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture. Carcinogenesis 14:781-783.
13. Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54:1295-1310.
14. Gatmaitan ZC and Arias IM (1993) Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24:77-97.
15. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360.
16. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, and Axelrod J (2000) Neuroprotective antioxidants from marijuana. Ann NY Acad Sci 899:274-282.
17. Kartner N, Shales M, Riordan JR, and Ling V (1983) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43:4413-4419.
18. Killestein J, Uitdehaag BM, and Polman CH (2003) Cannabinoids and immune function. J Am Med Assoc 290:754, 755.
19. Lieberman DM, Reithmeier RA, Ling V, Charuk JH, Goldberg H, and Skorecki KL (1989) Identification of P-glycoprotein in renal brush border membranes. Biochem Biophys Res Commun 162:244-252.
20. Masereeuw R, Moons MM, and Russel FG (1997) Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur J Pharmacol 321:315-323.
21. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, and Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308:838-845.
22. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, and Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Investig 100:2430-2436.
23. Mechoulam R, Parker LA, and Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S.
24. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, and Stadelmann AM (2005) Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27:799-810.
25. Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, and Kaneo S (2005) Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 78:43-51.
26. Pertwee RG and Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:101-121.
27. Reid MJ and Bornheim LM (2001) Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 61:1357-1367.
28. Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178:107-115.
29. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, and Borst P (1995a) Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295-1298.
30. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995b) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Investig 96:1698-1705.
31. Shapiro AB and Ling V (1994) ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 269:3745-3754.
32. Smit JW, Weert B, Schinkel AH, and Meijer DK (1998) Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther 286:321-327.
33. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, and McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16-21.
34. Vaccani A, Massi P, Colombo A, Rubino T, and Parolaro D (2005) Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144:1032-1036.
35. van Bree JB, de Boer AG, Danhof M, Ginsel LA, and Breimer DD (1988) Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 247:1233-1239.
36. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, and Breimer DD (2000) Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 11:207-214.
37. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, and van Meer G (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87:507-517.
38. Wang JS, DeVane CL, Donovan JL, Gibson BB, Gefroh HA, and Markowitz JS (2004a) Cannabinoids stimulate ATPase activity of P-glycoprotein. Neuropsychopharmacology 29 (Suppl 1):S73.
39. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, and Lindsay De Vane C (2004b) Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29:551-557.
40. Zhu HJ and Liu GQ (2003) Effect of E6, a novel calmodulin inhibitor, on activity of P-glycoprotein in purified primary cultured rat brain microvessel endothelial cells. Acta Pharmacol Sin 24:1143-1149.